alpha glucosidase inhibitors market is poised to grow by $567.96 mn during 2022-2026, accelerating at a CAGR of 2.51%
The market is driven by increase in awareness of diabetes and growing initiatives, growing awareness about benefits of alpha glucosidase inhibitors, and increasing prevalence of dumping syndrome globally
DUBLIN--(BUSINESS WIRE)--Nov 16, 2022--
The alpha glucosidase inhibitors market is poised to grow by $567.96 mn during 2022-2026, accelerating at a CAGR of 2.51%
The market is driven by increase in awareness of diabetes and growing initiatives, growing awareness about benefits of alpha glucosidase inhibitors, and increasing prevalence of dumping syndrome globally.
This study identifies the growing geriatric population as one of the prime reasons driving the alpha glucosidase inhibitors market growth during the next few years. Also, availability of novel and improved alpha glucosidase inhibitors and increasing r and d on alpha glucosidase inhibitors will lead to sizable demand in the market.
The report on the alpha glucosidase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The alpha glucosidase inhibitors market analysis includes the disease type segment and geographic landscape.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alpha glucosidase inhibitors market vendors. Also, the alpha glucosidase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
3.2 Market segment analysis
3.4 Market outlook: Forecast for 2021-2026
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
5 Market Segmentation by Disease Type
5.2 Comparison by Disease Type
5.3 Type 2 diabetes - Market size and forecast 2021-2026
5.4 Dumping syndrome - Market size and forecast 2021-2026
5.5 Market opportunity by Disease Type
6.1 Customer landscape overview
7.1 Geographic segmentation
7.2 Geographic comparison
8 Drivers, Challenges, and Trends
8.3 Impact of drivers and challenges
10.2 Market positioning of vendors
Anderson Hay and Grain Co. Inc.
AstraZeneca Plc
Bayer AG
BioVision Inc.
Border Valley Trading
Bristol Myers Squibb Co.
C. H. Boehringer Sohn AG and Co. KG
Eli Lilly and Co.
GSK Plc
Glenmark Pharmaceuticals Ltd
Merck KGaA
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi
Straight Healthcare
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH DIABETES
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/16/2022 09:29 AM/DISC: 11/16/2022 09:29 AM
http://www.businesswire.com/news/home/20221116005669/en